Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab

Nivolumab improves the prognosis of non-small cell lung cancer (NSCLC) but can cause immune-related adverse events (irAEs). Reports have indicated longer progression-free survivals (PFSs) in patients with irAEs than in those without irAEs. We reported associations between programmed death ligand-1 (...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Sci Rep
Huvudupphovsmän: Funazo, Tomoko Yamamoto, Nomizo, Takashi, Ozasa, Hiroaki, Tsuji, Takahiro, Yasuda, Yuto, Yoshida, Hironori, Sakamori, Yuichi, Nagai, Hiroki, Hirai, Toyohiro, Kim, Young Hak
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group UK 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6864095/
https://ncbi.nlm.nih.gov/pubmed/31745135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-53327-7
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk